Who stopped the research of several drugs against COVID-19

The world health organization (who) announced the termination of clinical trials of hydroxychloroquine and the combination of lopinavir/ritonavir in the treatment of coronavirus infection. The decision was made in accordance with the recommendation of the international coordinating Committee of the so-called studies of solidarity, which is devoted to the study of experimental methods of treatment COVID-19, reported on the who website.

According to the conclusion of the coordinating Committee, the use of hydroxychloroquine or a combination of lopinavir/ritonavir compared with standard therapy actually reduces mortality among hospitalized patients with COVID-19 patients. This conclusion was made based on the available data of clinical trials data treatment methods.

In addition, several studies revealed problems of security, which also affirmed the need to end further studies of hydroxychloroquine and the combination of lopinavir/ritonavir.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

Destiny Pharma has successfully tested a new antibiotic

The British company Destiny Pharma presented a compelling interim results of phase IIb studies of its experimental antibiotics, XF-73. During testing, the drug proved safe for human consumption, says PharmaTimes. Destiny Pharma specializiruetsya on the creation of new options for treating nosocomial infections, which would help patients in the spread of drug resistance microorganisms. Platform […]

FAS has hampered the growth of prices on loperamide and doxycycline

The arbitration court of Moscow upheld the position of the FAS in a dispute with “Velform”: the company tried to challenge the refusal of the Antimonopoly authority in the approval of maximum selling prices of drugs Loperamide Welfarm (loperamide) and Welfarm Doxycycline (doxycycline). In the course of economic analysis of the FAS revealed that submitted […]

Russian vaccine against coronavirus will go into circulation on 1 January 2021

Developed by the center of Gamaliel vaccine against coronavirus infection was registered by the Ministry of health of the Russian Federation. The planned delivery of the drug into circulation on 1 January 2021, reports TASS. Earlier, the Association of clinical research (AOKI) said about the need to postpone state registration of domestic vaccines against coronavirus […]

Named manufacturer of the first domestic vaccine for COVID-19

The vaccine, developed by the “NICAM them.F. Gamalei” was registered by the Ministry of health. The only platform for vaccine production in Russia, in addition to NICAM, will be a pharmaceutical plant, Binnopharm in Zelenograd. Mass production of the vaccine is planned to start by the end of 2020. “NICAM them.F. Gamalei” one of the […]